# US 2019/0167725 A1 · Composition and method for improving efficacy of stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167725 A1
- Document ID: US20190167725A1
- Status: Published application
- Kind: A1
- Application number: 16/078,989
- Filed: 2017-02-22
- Published: 2019-06-06
- Earliest claimed: 2016-02-23
- Assignees: University-Industry Cooperation Group of Kyung Hee University
- Applicants: University-Industry Cooperation Group of Kyung Hee University
- Inventors: Ki-Sook PARK; Jingyeong YU
- Web page: https://patentgrep.com/patent/US20190167725A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a method for increasing one or more selected from the group consisting of mobility, an engraftment ability, a CFU-F-forming ability, an anti-inflammatory immunosuppression induction function, and an angiogenesis-promoting ability of stem cells, comprising treating stem cells with a short-chain fatty acid or a salt thereof. According to the present invention, the method can readily prepare, in large quantities, stem cells having high mobility, an excellent colony formation ability, and an excellent engraftment ability so as to have excellent biocompatibility to a human body, using a low-cost short-chain fatty acid derived from a human body or a salt thereof.

## Claims

### Claim 1

A method for enhancing one or more stem cell functions selected from the group consisting of mobility, an engraftment ability, a CFU-F-forming ability, an anti-inflammatory immunosuppression-inducing function, and an angiogenesis-promoting ability of stem cells, comprising treating stem cells with a short-chain fatty acid or a salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the short-chain fatty acid is one or more selected from acetic acid, propionic acid, butyric acid, caproic acid (C6), caprylic acid (C8), capric acid (C10), lauric acid (C12), myristic acid (C14), palmitic acid (C16), stearic acid (C18), oleic acid (C18:1) elaidic acid (C18:1), linoleic acid (C18:2), α-linolenic acid (C18:3), γ-linolenic acid (C18:3), arachidonic acid (C20:3), eicosapentaenoic acid (C20:5), docosahexaenoic acid (C22:6), 5,6-epoxyeicosatrienoic acid, and 8,9-epoxyeicosatrienoic acid.

### Claim 3 (depends on 1)

The method of claim 1, wherein the stem cells are mesenchymal stem cells or hematopoietic stem cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein the treatment of stem cells with the short-chain fatty acid or salt thereof is performed ex vivo or in vitro.

### Claim 5 (depends on 1)

The method of claim 1, wherein the treatment of stem cells with the short-chain fatty acid or salt thereof is performed in serum-free DMEM medium or RPMI1640 for 3 hours to 14 days.

### Claim 6

A method for enhancing one or more stem cell functions selected from the group consisting of mobility, an engraftment ability, a CFU-F formation ability, an anti-inflammatory immunosuppression-inducing function, and an angiogenesis-promoting ability of stem cells, comprising a short-chain fatty acid or a salt thereof as an active ingredient.

### Claim 7 (depends on 6)

The method of claim 6, wherein the short-chain fatty acid is one or more selected from acetic acid, propionic acid, butyric acid, caproic acid (C6), caprylic acid (C8), capric acid (C10), lauric acid (C12), myristic acid (C14), palmitic acid (C16), stearic acid (C18), oleic acid (C18:1) elaidic acid (C18:1), linoleic acid (C18:2), α-linolenic acid (C18:3), γ-linolenic acid (C18:3), arachidonic acid (C20:3), eicosapentaenoic acid (C20:5), docosahexaenoic acid (C22:6), 5,6-epoxyeicosatrienoic acid, and 8,9-epoxyeicosatrienoic acid.

### Claim 8 (depends on 1)

Stem cells prepared according to the method of claim 1.

### Claim 9 (depends on 8)

A cell therapy composition comprising the stem cell of claim 8.

### Claim 10

A method for promoting migration of bone marrow-derived hematopoietic stem cells into the peripheral blood in a subject excluding humans, comprising administering a short-chain fatty acid or a salt thereof to the subject.

### Claim 11

A composition for enhancing one or more stem cell functions selected from the group consisting of mobility, an engraftment ability, a CFU-F formation ability, an anti-inflammatory immunosuppression-inducing function, and an angiogenesis-promoting ability of stem cells, comprising a short-chain fatty acid or a salt thereof as an active ingredient.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the short-chain fatty acid is one or more selected from acetic acid, propionic acid, butyric acid, caproic acid (C6), caprylic acid (C8), capric acid (C10), lauric acid (C12), myristic acid (C14), palmitic acid (C16), stearic acid (C18), oleic acid (C18:1) elaidic acid (C18:1), linoleic acid (C18:2), α-linolenic acid (C18:3), γ-linolenic acid (C18:3), arachidonic acid (C20:3), eicosapentaenoic acid (C20:5), docosahexaenoic acid (C22:6), 5,6-epoxyeicosatrienoic acid, and 8,9-epoxyeicosatrienoic acid.

### Claim 13 (depends on 11)

The composition of claim 11, wherein the stem cells are mesenchymal stem cells or hematopoietic stem cells.

### Claim 14 (depends on 2)

Stem cells prepared according to the method of claim 2.

### Claim 15 (depends on 3)

Stem cells prepared according to the method of claim 3.

### Claim 16 (depends on 4)

Stem cells prepared according to the method of claim 4.

### Claim 17 (depends on 5)

Stem cells prepared according to the method of claim 5.